A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ELA026 Following Intravenous and/or Subcutaneous Administration of Single and Multiple Doses in Healthy Adults
Latest Information Update: 01 Apr 2024
At a glance
Most Recent Events
- 26 Mar 2024 Status changed from recruiting to completed.
- 18 Oct 2023 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.
- 18 Oct 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2024.